Bellerophon therapeutics, inc. (BLPH)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-12,769

-15,480

-16,915

-14,510

Net Income (Loss) Attributable to Parent

-4,970

-4,080

-4,287

-4,105

-795

-912

11,101

-11,471

4,096

-24,159

-7,586

-3,930

-19,143

-7,423

-4,195

-5,137

-7,059

-10,826

-11,142

-11,583

-12,908

-

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Fair Value Adjustment of Warrants

894

-178

-215

-673

-1,616

-3,676

-17,840

3,689

-7,050

16,948

1,435

-2,367

14,387

590

0

0

0

-

-

-

-

-

-

-

-

Accretion and amortization of discounts and premiums on marketable securities, net

-

-

-

-

-

-

-

2

-1

-

-

0

0

-

-6

-8

-15

-

-5

0

0

-

-

-

-

Stock based compensation

468

391

174

579

1,008

840

504

895

716

707

756

649

729

610

779

768

601

507

437

363

444

540

263

765

271

Depreciation

46

85

87

88

88

91

90

90

91

90

91

93

99

99

99

98

104

104

90

91

92

94

96

96

102

Changes in operating assets and liabilities:
Receivables due from Ikaria, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

83

0

167

-

-

-

-

Prepaid expenses and other current assets

-56

-307

-113

-123

298

-1,088

-753

-525

-343

-575

-1,428

-1,080

111

-34

960

-322

342

3,941

-395

-135

372

31

145

-78

-48

Restricted cash held for Ikaria, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,318

-2,315

-

-

-

-

Increase (Decrease) in Restricted Cash for Operating Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,314

17,756

Other non-current assets

-

-

-

-

-

-44

18

-14

-14

-5

-403

-447

-582

-1,813

-2,291

-390

-716

6,701

0

0

0

-

-

-

-

Accounts payable, accrued research and development, and accrued expenses

-830

-

168

-428

-727

-

35

643

1,345

-

244

-596

-200

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable, accrued research and development, and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-739

-

-2,488

-735

1,397

-

-708

352

12

Amounts due to Ikaria, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11

-

-20

182

408

-

-

-

-

Increase in amounts due to Ikaria, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,245

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,324

-4,777

-6,693

-

-

-9,229

-8,791

-12,391

-14,783

-12,800

-30,588

Net cash used in operating activities

-4,336

-2,894

-3,960

-3,742

-2,340

-4,060

-5,374

-5,617

-444

-4,497

-3,229

-4,513

-3,657

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Capital expenditures

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

22

34

424

0

0

-

-

-

-

Purchase of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

3,892

14,700

4,165

0

-

-

-

-

Proceeds from sale of marketable securities

-

-

-

-

-

-

-

-

-

3,183

1,725

1,192

2,458

1,655

4,681

4,160

1,725

3,440

1,470

0

0

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

184

723

-788

2,458

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from sale of Units in PIPE Offering, net of offering expenses

-

-

-

-

-

-

0

0

-28

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,681

4,160

1,703

-

-

-4,165

0

-

-

-

-

Proceeds received from exercise of warrants

3,100

0

0

0

0

-

-

-

-

1,552

227

0

520

0

0

0

0

-

-

-

-

-

-

-

-

Contribution from Ikaria, Inc. in connection with Spin-Out

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

80,000

Contributions from Ikaria, Inc., net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

9,252

Payment of offering expenses related to the secondary offering

-

-

-

-

-

-

-

-

-

-

0

0

235

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock in Public Offering

0

-

0

-138

6,374

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of membership units

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1

-

-

-

-

Payment of offering expenses related to the PIPE offering

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of Units in Direct Offering, net of commissions and offering expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

Cash proceeds from issuance of common stock from initial public offering, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-1,083

54,910

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,269

651

0

-

-

-1,032

54,911

-1,399

692

-1,168

89,252

Net cash provided by (used in) financing activities

3,057

-69

0

-138

6,374

0

25

169

-28

1,105

23,664

2,730

285

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, cash equivalents and restricted cash

-1,279

-2,963

-3,960

-3,880

4,034

-3,061

-3,850

-4,946

-472

-3,208

21,158

-2,571

-914

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash financing activities:
Net change in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,626

34

-4,990

-17,648

-24,601

-14,426

46,120

-13,790

-14,091

-13,968

58,664

Non-cash investing activities:
Unpaid expenses related to offerings

0

-

-

-

138

-

-

-

720

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in unrealized holding gains on marketable securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3

0

21

-20

1

0

0

-

-

-

-

Contribution of property, plant and equipment from Ikaria, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

7,491

Non-cash financing activities:
Conversion of warrant liability to common stock upon exercise of warrants

-

-

-

-

-

-

-

-

-

3,406

303

0

702

0

0

0

0

-

-

-

-

-

-

-

-